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Hepatocellular carcinoma (HCC) is one of the most
common human malignancies. The majority of HCCs
occur in a background of cirrhosis related to hepatitis B
virus, hepatitis C virus, or alcoholism. The presence of
cirrhosis has significant impact on the management of the
cancer. The impairment of liver function as a result of
cirrhosis restricts the treatment options, and cirrhosis is
also known to predispose to multicentric hepatocarcino-
genesis and increase the risk of recurrence after resection
of HCC.1 The advent of liver transplantation and radio-
frequency ablation have provided better chances of
curative treatment for patients with small HCC detected by
screening in recent years; however, hepatic resection
remains the mainstay of curative treatment for HCC asso-
ciated with Child-Pugh class A cirrhosis.2 While the
perioperative safety and long-term survival of liver resec-
tion in cirrhotic liver have improved in recent years, the
rate of postoperative recurrence of HCC remains high.3
In more than 80% of the cases of postoperative recur-
rence after resection of HCC, the recurrent tumors occur in
the liver remnant.1 The mechanisms of intrahepatic recur-
rence can be either intrahepatic metastasis from the initial
tumor or a de novo multicentric tumor. Differentiation of
the two has potential implications on surveillance, pre-
vention, and management strategies for recurrence.
Clinically, it is impossible to distinguish the two based on
imaging appearances. The only definitive way of differ-
entiation is by genetic or molecular studies of the clonal
origin of the tumors, which are technically complicated and
cannot be used in clinical practice.4,5 Hence, several groups
of authors have attempted to differentiate intrahepatic
metastasis and multicentric recurrence based on the inter-
val of development of recurrence from the time of resection
and risk factors associated with the recurrence.6–8 These
studies have consistently demonstrated that early recur-
rence within the first 2 years after resection of HCC is
likely to be associated with aggressive tumor pathological
factors such as high tumor grade, microvascular invasion,
and microsatellite lesions, whereas late recurrence is more
likely related to underlying liver conditions such as the
presence of cirrhosis and hepatitis activity. Such results
suggested that early recurrence is most likely the conse-
quence of occult metastasis from the initial tumor, whereas
late recurrence more likely represents multicentric tumors.
Cucchetti et al.9 conducted a study on the risk factors
associated with early and late recurrence in 204 patients
with cirrhosis who had undergone resection of HCC. The
authors identified high alpha-fetoprotein level, poorly dif-
ferentiated tumor, and microvascular invasion as the risk
factors for early recurrence within 2 years after resection,
and male gender, older age, high transaminase levels,
multiple primary tumors, and high alpha-fetoprotein level
as risk factors for late recurrence beyond 2 years. These
findings are generally in line with those of previous stud-
ies.6–8 To demonstrate that late recurrence is most likely
related to new multicentric tumor development in the cir-
rhotic liver, the authors further compared the incidence and
risk factors of late recurrence in resected patients with the
those of development of HCC in a cohort of 150 cirrhotic
patients undergoing regular surveillance of HCC. Such data
are not available in previous studies and provide a better
insight into the risk of late recurrence after resection of
HCC in cirrhotic patients. The authors showed that the risk
factors for development of HCC in a group of cirrhotic
patients undergoing surveillance were similar to the risk
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factors for late recurrence after resection of HCC in cir-
rhotic patients. Interestingly, after stratification by risk
factors, the annual incidence of recurrence (6.2% per year)
in low-risk (\2 risk factors) resected patients was similar to
the annual incidence of HCC (5.8% per year) in the cirrhotic
patients with high risk profile (C2 risk factors). The risk of
development of HCC was the highest in the resected group
with C2 risk factors (26.7% per year) and lowest in cirrhotic
patients with\2 risk factors. The data suggested that while
cirrhotic patients with resection of HCC and those with
cirrhosis had similar risk factors for development of new
HCC, the former group was at a higher risk of further
developing new tumors with the already manifested HCC.
The new findings of the study of Cucchetti et al.9 may
provide guidance on the optimum surveillance strategy
after resection of HCC. Currently, the development of
recurrence after resection of HCC is surveyed by regular
ultrasonography or contrast computed tomography scan
every 3 months in most centers in order to detect early
recurrence that can be treated effectively by re-resection,
ablation, or transarterial chemoembolization.
Cucchetti et al.9 suggested that strict surveillance should
be applied for the first 2 years, but in those with no
recurrence after 2 years and low risk for late recurrence, a
less stringent surveillance scheme similar to that of sur-
veillance for HCC in cirrhotic patients (i.e., 6-month
surveillance) can be applied. Such a strategy seems to
make sense as a cost-effectiveness consideration. However,
there are some caveats in advocating such a strategy. First,
the stratification of risk factors in this study was based on a
small sample size of late recurrence in resected patients
and occurrence of HCC in cirrhotic patients. Further
studies are needed in larger patient population to define the
best stratification of patients according to risk of recurrence
of HCC. Furthermore, there are other potential risk factors
related to the underlying viral etiology that could be
potentially incorporated into the risk-stratification system
in future studies. For instance, in hepatitis B virus related
HCC, recent evidence suggested that patients with hepatitis
E antigen or high hepatitis B virus DNA level are at higher
risk of recurrence after resection of HCC.10,11 Second,
patients who have undergone resection of HCC may have
more restricted options of treatment, particularly re-resec-
tion, because of the previous partial hepatectomy. It may be
of particular advantage to diagnose recurrent tumor earlier
in patients who have already had hepatic resection so that
less invasive local ablation can be applied. Third, it has to
be borne in mind that the stratification of early and late
recurrence at 2 years after resection is somewhat arbitrary.
While risk factor analysis of early and late recurrence
provides insight into the likely mechanism and risk of
recurrence in a patient population, it may not specifically
predict the risk of recurrence in a patient. For instance, in a
patient with a large tumor with microvascular invasion who
has no recurrence within the first 2 years after resection,
the risk of recurrence due to an occult microscopic
metastasis beyond 2 years remains substantial even if the
patient’s underlying liver condition is at low risk of
developing a late multicentric recurrence. It may be pru-
dent to advise more stringent surveillance in such a patient
even after 2 years. Currently, the biological behavior of
HCC remains largely unpredictable. Before any effective
adjuvant therapy is available, early detection and effective
treatment of recurrence is the most practical way to prolong
patient survival. The cost-effectiveness and the survival
benefit of different intervals of postresection surveillance
for HCC need to be studied in greater detail in this specific
setting before making a recommendation.
The differentiation of early and late recurrence may also
have implications on strategies in adjuvant therapy to
prevent recurrence. To date, no adjuvant therapies have
been conclusively demonstrated to prevent recurrence.
However, active clinical trials are being conducted to use
new drug therapies to prevent recurrence. One approach is
to use molecular targeting drugs that aim at inhibition of
tumor cell proliferation, invasion, or angiogenesis.12 For
such an approach that aims at prevention of growth of
micrometastasis from the initial tumor, the endpoint of the
trial should be prevention of early recurrence within the
first 2 years. In contrast, adjuvant strategies that aim at
modulation of the underlying liver condition should target
prevention of late recurrence as the end point. For hepatitis
virus related HCC, antiviral therapy may be able to reduce
hepatitis activity in the cirrhotic liver and decrease the
chance of multicentric development of HCC. A random-
ized trial of lamivudine versus placebo in cirrhotic patient
population has shown that lamivudine reduces the risk of
development of HCC.13 The effect of antiviral therapy on
incidence of multicentric recurrence after resection of
hepatitis B virus related HCC is certainly worthwhile to
study. For hepatitis C virus related HCC, there is some
evidence that interferon may reduce late recurrence after
resection of HCC in a randomized controlled trial, though
this needs to be verified in further studies.14
Finally, the differentiation of the mechanisms of early
recurrence and late recurrence may have an important
implication on treatment of recurrence, especially in the
consideration of salvage transplantation for recurrence.15,16
Early recurrence is more likely related to micrometastasis
from the initial tumor and may be a less favorable candi-
date for salvage transplantation, especially for those
patients with multinodular recurrence representing wide-
spread micrometastases. On the other hand, a patient with a
small late multicentric recurrence after resection of HCC is
a more favorable candidate for salvage transplantation,
with prognosis probably similar to that of primary
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transplantation for a newly diagnosed small HCC. For
cirrhotic patients with high risk of late recurrence as
demonstrated by risk stratification and low risk for early
recurrence from micrometastasis based on the histological
analysis of the resected tumor, it may also be reasonable to
consider liver transplantation prior to the development of
recurrence. It remains debatable which strategy of salvage
transplantation is better, but to some extent this depends on
local availability of liver grafts.
In conclusion, risk factor studies of early and late
recurrence have provided significant evidence of different
mechanisms of early and late recurrences after resection of
HCC. The additional knowledge of risk of late recurrence
after resection of HCC in cirrhotic patients compared with
risk of occurrence of HCC in general cirrhotic patients
sheds insight into a new strategy of surveillance for
recurrence based on risk of late recurrence. The differen-
tiation of early and late recurrences also has important
implications on prevention and treatment of recurrences,
which are the most important areas of study to improve the
long-term prognosis after resection of HCC.
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